16 th World Congress of Anaesthesiologists 28 August – 2 September 2016 Hong Kong Convention and Exhibition Centre FINAL PROGRAMME Rapid recovery. Efficient patient throughput. 1 Rapid Recovery impacts your patients and improves PACU efficiency.1,2 DESFLURANE PRESCRIBING INFORMATION This prescribing information is based on the HK Package Insert and is intended for international use only. Please always consult your full country-specific SPC as licenses and licensing conditions may vary from country to country. Name and composition: Desflurane 100% v/v Inhalation vapour, liquid. Indications: Inhalation agent for induction and/or maintenance of anaesthesia in adults, maintenance of anaesthesia in paediatrics. Dosage and Route: See SPC for full details. Administration by inhalation using vapouriser specifically designed for use with desflurane and dose individual- ised based on patient’s response. MAC decreases with increasing age. Induction: End-tidal concentrations of 4-11% usually produces surgical anaesthesia in 2-4 minutes. Not for induction in paediatrics. Maintenance: 2.5-8.5% with or without concomitant nitrous oxide. 5.2-10% with or without nitrous oxide in paediatrics. Not for use in non-intubated children. Concentrations of 1-4% have been used successfully in chronic renal/hepatic impairment and renal transplant. Side effects: Nausea and vomiting has been reported postoperatively – may be due to a range of factors and common following surgery under general anaesthesia. Common (≥1/100 - <1/10) Pharyngitis, breath holding, headache, conjunctivitis, nodal arrhythmia, bradycardia, tachycardia, hypertension, apnea, cough, laryngospasm, salivary hypersecretion. Precautions: Only to be administered by people trained in administration of general anaesthesia with appropriate emergency measures available. Monitor blood pressure and heart rate as part of evaluation of the depth of anaesthesia. Caution in use with LMA or face mask in children under 6 years. May trigger malignant hyperthermia. Inhaled anaesthetics have been associated with increases in serum potassium. Prompt and vigorous treatment for hyperkalaemia and arrhythmias recommended. Disruption of hepatic function, icterus and fatal liver necrosis have been reported with halogenated anaesthetics. May increase CSF pressure but attention to maintain CPP. Hypotension and respiratory depression increases as anaesthesia deepens. Carbon dioxide absorbers should not dry out. Appropriate analgesia should be administered at the end of surgery or early in PACU. Caution with repeated anaesthesia in a short period of time. Desflurane has been associated with some glucose elevation intra-operatively. Safety of desflurane has not been established in obstetric procedures. Contra-indications: Not to be used if general anaesthesia in contra-indicated, known hypersensitivity to halogenated agents or known susceptibility to malignant hyperthermia. Interactions: MAC reduced by concomitant N2O administration. Concomitant administration of opioids or benzodiazepines show a marked reduction in MAC. Neuromuscular blocks are potentiated by desflurane. Overdose: Discontinue desflurane, establish clear airway and initiate assisted/controlled ventilation with pure oxygen. Support and maintain adequate haemodynamics. For posology, incompatibilities and interactions, please refer to the full SPC. 1. Beaussier M, Decorps A, Tilleul P, et al. Can J Anesth 2002;49:339-346. 2. Dexter F, Bayman EO, Epstein RH. Anesth Analg 2010;110:570-580. Baxter and Suprane are trademarks of Baxter International Inc. Baxter Healthcare Ltd. Suite 2701-3, 27/F Oxford House, Taikoo Place 979 King’s Road, Island East, Hong Kong Tel: (852) 2807-8500 Fax: (852) 2807-8596 HK/MG27/16-0001a Date of Preparation: Jun 2016 Contents Welcome messages ..................................................................................................................... 4 Committees ......................................................................................................................................... 9 Acknowledgements ..................................................................................................................11 About WFSA ...................................................................................................................................12 WFSA Award winners ............................................................................................................12 General information ................................................................................................................14 Networking events ....................................................................................................................15 Scientific information .............................................................................................................16 Invited faculty list ......................................................................................................................17 Programme overview .............................................................................................................22 Programme per track ..............................................................................................................42 Workshops and PBLDs programme ..........................................................................78 ePoster discussions ................................................................................................................108 Related meetings .....................................................................................................................156 Industry symposia programme ...................................................................................157 Product presentations .........................................................................................................161 Fellowship programme ......................................................................................................163 Exhibitors and sponsors profile ..................................................................................165 Exhibitors list ...............................................................................................................................197 Exhibition floor plan ............................................................................................................198 Venue plans ..................................................................................................................................200 3 Welcome messages Welcome to the 16th World Congress of Anaesthesiologists (WCA) in Hong Kong from 28th August to 2nd September 2016! This is a joint meeting between the Society of Anaesthetists of Hong Kong (SAHK) and the World Federation of Societies of Anaesthesiologists (WFSA) whose objectives are to make available the highest standards of anaesthesia, pain treatment, trauma management and resuscitation to all peoples of the world. With this in mind, our organising committee has put together a comprehensive and clinically relevant programme that will update you on the latest standards and innovations in anaesthesia, pain medicine and intensive care. Lectures, industry symposia and workshops will encourage interaction between participants and en- sure, quite literally, something for everyone. The World Congress is the Olympics of the Anaesthesia world, keenly anticipated as it travels the globe and a wonderful occasion to bring all the international practitioners of our specialty together. Although our backgrounds and resources may be very different, we all face similar problems and challenges in providing the very best care to our patients. WCA is the preeminent Anaesthesia congress and only takes place every four years. The programme features 20 different scientific tracks organised by leaders in each field, together with symposia on Anaesthesia and Cancer, Obesity and Sleep Medicine and you can learn about Anaesthesia with Chinese characteristics with the Chinese Society of Anesthesiology. Our aim is to provide first-rate, global, scientific content that is also clinically relevant with a strong practical emphasis. I’m grateful to all those who have submitted the 800 scientific abstracts and hope you will enjoy and benefit from presentation and discussion with colleagues and peers in your field. Hong Kong is “Asia’s World City” - the most vibrant city in the world with a dynamic and fascinating history. A safe, cos- mopolitan and friendly place with excellent infrastructure, Hong Kong is strategically located in the heart of Asia. With so many things to see and do where “East meets West” you will be spoilt for choice with our superb and varied restaurants, excellent competitively priced hotels, shopping, beaches, country parks and natural beauty. If that is not enough, we have a social schedule with something for everyone. Join us for a networking evening in a relaxed atmosphere at the 100-year heritage building, Western Market, take a helicopter ride over the island or join a small group history lecture tour. Make the most of your visit to our unique city, you won’t be disappointed! (I only intended to be here for a year myself...in 1992). Michael Irwin President of WCA 2016 www.wca2016.com | WCA 2016 - Final Programme Final - 2016 WCA 4 Welcome to the “Olympic Games of Anaesthesia Congresses” to be held at the Hong Kong Conference Centre August 28 - September 2, 2016. This 16th World Congress of Anaesthesiologists has been organised by